MAPT and Alzheimer disease: These proteinopathies are associated with the loss of synapses and subsequent neuronal cell loss in the entorhinal cortex, hippocampus, and frontal cortex[1–3], and currently, the biomarkers most commonly used in human AD studies are beta-amyloid 42, tau, and phospho-tau proteins in the cerebrospinal fluid.